Waldenstrom Macroglobulinemia research hub
18 indexed studies · 8 currently recruiting
- active not recruitingPHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
This study looks at a new drug, Iopofosine I-131, for people with certain B-cell cancers like Waldenstrom, myeloma, or lymphoma, who haven't responded well to other treatments. It aims to see how safe and effective this new approach is.
United States · Australia · Brazil - active not recruitingPHASE2
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
This study looks at new treatments, zilovertamab vedotin alone or with nemtabrutinib, for certain B-cell lymphomas like Mantle Cell Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia. It checks how safe and effective these treatments are for people whose cancer has returned or didn’t respond to previous therapies.
United States · Brazil · Canada - authorisedTherapeutic exploratory (Phase II)
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
This study looks at a new drug, pirtobrutinib, for older patients with mantle cell lymphoma who might be too unwell for standard treatments. It aims to see how well the drug works to stop the cancer from growing and how safe it is.
Italy - active not recruitingPHASE2
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
This study looks at new drug combinations for untreated Mantle Cell Lymphoma in people aged 18-79. It compares two approaches: one with Ibrutinib and a CD20 antibody, and another adding Venetoclax, to see how well they work.
Belgium · France · United Kingdom - recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
This study is looking at a new combination of medicines, sonrotoclax plus zanubrutinib, for adults in the UK with a type of blood cancer called Mantle Cell Lymphoma. It aims to see if this combination works better and is safe when their cancer has come back or isn't responding to other treatments.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
This study is testing a new drug, BGB-11417, for people with mantle cell lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well it works.
United States · Argentina · Belgium - recruitingPHASE1, PHASE2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
This study looks at new ways to give a medicine called sonrotoclax for blood cancers like Chronic Lymphocytic Leukemia (CLL). We want to find the safest and most effective starting dose schedule, often with another medicine called zanubrutinib, to help patients.
United States · Australia · France - authorisedTherapeutic exploratory (Phase II)
A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)
This study looks at a new drug, glofitamab, for people with a type of blood cancer called Mantle Cell Lymphoma. It's for patients whose cancer has come back or hasn't responded well to a previous treatment called CAR T-cell therapy.
Italy - recruitingPHASE2
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
This study is looking at a new treatment approach for a type of slow-growing (indolent) mantle cell lymphoma. It compares observing the condition with a combination of two drugs, zanubrutinib and rituximab, given for a set period, to see if earlier treatment is helpful.
United Kingdom - recruitingPHASE1
Study of SGR-1505 in Mature B-Cell Neoplasms
This study is testing a new medicine called SGR-1505 for certain types of B-cell lymphoma. We want to find out if it's safe, what dose works best, and if it can help slow down the disease. It's for people whose treatment hasn't worked or stopped working.
United States · France · Italy - recruitingPHASE1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This study is testing a new medicine, IKS03, for people with certain types of advanced B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see how well it works. This is an early-stage study, meaning it's the first time it’s being given to people.
United States · Australia · Canada - recruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
This study looks at a new drug, Calquence, for adults with a type of blood cancer called Mantle Cell Lymphoma. Researchers want to see how many people respond to the treatment and how safe it is.
Poland · France - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial
This study looks at a new combination of medicines (MabThera, Polivy, and Bendamustin) for people with a type of blood cancer called mantle cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this treatment is.
Austria - recruitingPHASE1, PHASE2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
This study is testing a new drug, surovatamig, for different types of B-cell blood cancers like leukaemia and lymphoma. Researchers want to see if it's safe and effective, either alone or with other cancer treatments.
United States · Australia · China - ongoing, recruitingTherapeutic exploratory (Phase II)
Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)
This study is looking at a new treatment combination — rituximab, bendamustine, cytarabine, and venetoclax (V-RBAC) — for older patients with a specific type of blood cancer called mantle cell lymphoma. It aims to see how well this new treatment stops the cancer from growing for at least two years.
Italy - active not recruitingPHASE2
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
This study is looking at a new combination of two drugs, acalabrutinib and rituximab, for older or less fit patients with a type of blood cancer called Mantle Cell Lymphoma. We want to see how safe and effective this treatment is.
United Kingdom